|Market Research A to Z | Company Profiles A to Z | Register | Contact Us | Shopping Basket|
|+44 (0) 203 086 8600 Call us on|
The global apheresis market is to reach a value of $1,922.4 million by 2017, growing from a previous revenue total in 2012 of $1,140.8 million. The CAGR growth from 2012 to 2017 is estimated at approximately 11%. The global apheresis market is based on a process which uses various technologies and leverage platforms to collect blood, and then to separate it into different components using centrifugation and membrane separation technology.
The apheresis market is driven by the advantages of apheresis collection over the whole blood collection, huge demand for plasma in plasma fractionation and research for new applications of therapeutic apheresis. However, the cost of capital investment involved and the challenges in recruiting donors for apheresis collection are inhibiting the growth of this market.
Developed markets account for a major share of the apheresis market, whereas emerging countries form the fastest growing markets. North America and Europe collectively contribute to more than 76.2% of the total apheresis market. Asian markets are expected to expand their share in the coming years due to increasing need of blood for transfusion & therapeutic apheresis due to a large population base in these countries.
The key growth strategies adopted by the companies have been studied between 2010 and 2012. Players in this market have adopted various strategies to expand their global footprint and increase market share. New product developments; agreements, partnerships and collaborations; mergers and acquisitions; and expansion are some of the major strategies adopted by players to achieve growth. Agreements, collaborations, joint ventures and partnerships accounted for 42% of the key growth strategies by key players such as Fresenius Medical Care AG (Germany), Cerus Corporation (U.S.), and Haemonetics Corporation (U.S.). For example, in April 2012, Cerus Corporation signed a supply agreement with King Faisal Specialist Hospital, a Saudi Arabia based blood service provider. The agreement allowed the hospital to use the INTERCEPT Blood System to treat its platelet production of around 5,600 units per year.
Free Research Support: Let us do the work for you and find information from public and private sources of information. Contact us now and we can save you time and money.......Free Research Support
Use our skills and global network of researchers and consultants to help find and source the business information you need.
Contact us now on 00 44 (0) 203 0868600 or "enquiries @ companiesandmarkets.com" to discuss you requirements and we can provide you with a research solution at suprisingly efficient rates and timelines.
Sometimes we can even find the information you require for free.
We are offering our clients substantial savings on the best research available during January. Please contact us either via email or by calling our team to discuss your specific research needs on Tel: 00 44 (0) 203 0868600.